214 related articles for article (PubMed ID: 29858866)
1. The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data.
Anagnostis P; Siolos P; Christou K; Gkekas NK; Kosmidou N; Athyros VG; Karagiannis A
Hormones (Athens); 2018 Mar; 17(1):83-95. PubMed ID: 29858866
[TBL] [Abstract][Full Text] [Related]
2. Drugs for type 2 diabetes.
Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
[No Abstract] [Full Text] [Related]
3. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
[TBL] [Abstract][Full Text] [Related]
4. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Zhou JB; Tang X; Han M; Yang J; Simó R
Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
[TBL] [Abstract][Full Text] [Related]
5. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
Takahashi M; Shibasaki M; Echizen H; Kushiyama A
PLoS One; 2020; 15(7):e0236603. PubMed ID: 32706828
[TBL] [Abstract][Full Text] [Related]
6. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
[TBL] [Abstract][Full Text] [Related]
7. Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.
Noh Y; Kang DR; Kim DJ; Lee KJ; Lee S; Shin S
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1338-1346. PubMed ID: 28771933
[TBL] [Abstract][Full Text] [Related]
8. [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
Valerón PF; de Pablos-Velasco PL
Med Clin (Barc); 2013 Sep; 141 Suppl 2():20-5. PubMed ID: 24444520
[TBL] [Abstract][Full Text] [Related]
9. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
Thompson PL; Davis TME
Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
[TBL] [Abstract][Full Text] [Related]
13. [Drug treatment of type 2 diabetes].
Tielmans A; Laloi-Michelin M; Coupaye M; Virally M; Meas T; Guillausseau PJ
Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
[TBL] [Abstract][Full Text] [Related]
14. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
15. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular safety outcomes of new antidiabetic therapies.
LeBras MH; Barry AR; Koshman SL
Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
[TBL] [Abstract][Full Text] [Related]
18. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
